CW January 2004
Volume 13Issue Number 1 January 2004 ISSN 10593802 90Yttrium Ibritumomab Tiuxetan Radioimmunotherapy for Advanced NHL90Yttrium (90Y) ibritumomab tiuxetan (Zevalin®, Biogen Idec) radioimmunotherapy as consolidation therapy is feasible and well tolerated in patients with advanced follicular non-Hodgkin?s lymphoma (NHL) in remission following first-line chemotherapy, according to a presentation given at the 45th Annual Meeting of the American Society of Hematology.
Go to Previous Page Go to Next Page Source & Additional Reading 45th Annual Meeting of the American Society of Hematology Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
